JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "732057"
    }, 
    "description": "Angiogenesis, necessary for tumor growtti involves cell proliferation and directed migration. Ttius, there is clearly a crucial role of cytoskeletal microtubule (MT) dynamics in angiogenesis; linking perturbations of MT dynamics to Inhibition of tumor angiogeneisis. Our preliminary data strongly suggest that a semisynthetic tubulin-binding anticancer agent,(S)-3-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]-dioxolo[4,5- g]-iso-quinolin-5-yl)-6,7-dimethoxylsobenzofuran-1(3H)-one (EM011), has potent antiangiogenic activity (based upon NCI-DTP antiangiogenic drug screen). Our hypothesis is that EM011 will sen/e as an effective anticancer agent since it can target the MT cytoskeleton without causing any gross effects (over- or depolymerization of MTs) with concomitant antiangiogenic effects. The specific aims for the mentored phase were: Aim 1. Evaluation of the antiangiogenic efficacy of EM011. Aim 2. Determination of EM011's effect on the dynamic instability of MTs, HIF-lalpha expression and transactivation of downstream targets such as VEGF. We have successfully accomplished the proposed research in the K99 phase. Based upon the nontoxic attributes of EM011, we rationalize that combination of EM011 with other angiogenic inhibitors that function through independent mechanisms but show toxicity at their maximum tolerated doses (MTDs), presents a unique opportunity to reduce their doses to maximize therapeutic outcomes with decreased toxicity. The ROO phase of the project will focus on 2 aims: Aim 3. Investigation of potential synergistic antiproliferative and antiangiogenic effects of combinations of EM011 and ZD6474 (a tyrosine kinase inhibitor), or thalidomide (endothelial cell proliferation inhibitor) in breast (MDA-MB-231) and prostate (PC-3) cancer cells. Aim 4. Determination of the In vivo efficacy of EM011 and its synergistic combinations with ZD6474 or thalidomide, as inhibitors of experimental primary and metastatic breast and prostate cancers in real-time using non-invasive bioluminescent imaging.", 
    "endDate": "2014-08-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2441509", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2441509"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R00CA131489"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "therapeutic outcome", 
      "cytoskeletal microtubules", 
      "prostate", 
      "semisynthetic tubulin", 
      "endothelial cell proliferation inhibitor", 
      "independent mechanisms", 
      "thalidomide", 
      "inhibitors", 
      "antiangiogenic efficacy", 
      "angiogenesis", 
      "tumor growtti", 
      "nontoxic attributes", 
      "MTDs", 
      "preliminary data", 
      "prostate cancer", 
      "decreased toxicity", 
      "g]-iso-quinolin-5-yl)-6,7-dimethoxylsobenzofuran-1(3H)-one", 
      "Aim 1", 
      "migration", 
      "potent antiangiogenic activity", 
      "agents", 
      "crucial role", 
      "unique opportunity", 
      "downstream targets", 
      "NCI-DTP antiangiogenic drug screen", 
      "dynamic instability", 
      "ZD6474", 
      "gross effects", 
      "metastatic breast", 
      "cell proliferation", 
      "novel tubulin", 
      "EM011", 
      "EM011's effect", 
      "antiangiogenic effects", 
      "doses", 
      "Aim 4", 
      "antiangiogenic role", 
      "investigation", 
      "concomitant antiangiogenic effects", 
      "other angiogenic inhibitors", 
      "synergistic combination", 
      "project", 
      "anticancer", 
      "MT cytoskeleton", 
      "maximum", 
      "MT dynamics", 
      "dynamics", 
      "HIF-lalpha expression", 
      "aim", 
      "depolymerization", 
      "Ttius", 
      "transactivation", 
      "ROO phase", 
      "mentored phase", 
      "cancer cells", 
      "MDA-MB-231", 
      "toxicity", 
      "specific aim", 
      "VEGF", 
      "non-invasive bioluminescent imaging", 
      "experimental primary", 
      "perturbations", 
      "In Vivo Efficacy", 
      "evaluation", 
      "Aim 2", 
      "inhibition", 
      "hypothesis", 
      "tyrosine kinase inhibitors", 
      "determination", 
      "K99 phase", 
      "effective anticancer agents", 
      "combination", 
      "research", 
      "tumor angiogeneisis", 
      "breast", 
      "potential synergistic antiproliferative", 
      "PC-3"
    ], 
    "name": "Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.256304.6", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.256304.6", 
          "name": "GEORGIA STATE UNIVERSITY", 
          "type": "Organization"
        }, 
        "familyName": "ANEJA", 
        "givenName": "RITU", 
        "id": "sg:person.01365356361.20", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01365356361.20", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2441509"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2021-01-20T03:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_5.xml.gz", 
    "startDate": "2008-09-12T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=8321603"
  }
]

Download the RDF metadata as:  json-ld nt turtle xml License info

This table displays all metadata directly associated to this object as RDF triples.

121 TRIPLES      19 PREDICATES      99 URIs      91 LITERALS      5 BLANK NODES